Sign inJoin waitlistJoin the waitlist

Bora Lim

Director, Translational Research · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

2017-2017 Integrated Translational Science Center
2017
National Cancer Institute
2015
Hematology and Medical Oncology
Penn State Milton S Hershey Medical Center
2011–2014
Penn State Hershey Cancer Institute
2012–2014
Internal Medicine
University of Pennsylvania Health System
2007–2010
Catholic Medical Center
2004–2005
Doctor of Medicine
2000–2004

Research

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Annals of Oncology · 2021 · 855 citations
Inflammatory breast cancer biology: the tumour microenvironment is key
Review · Nature reviews. Cancer · 2018 · First of 5 authors · Corresponding · 267 citations
Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis
Nature Immunology · 2020 · 226 citations

Naoto Ueno
56 papers
Vicente Valero
29 papers
SM
Stacy Moulder
22 papers
Wendy Woodward
19 papers
Jennifer Litton
18 papers
Lei Huo
16 papers
Alastair Thompson
15 papers
Anthony Lucci
15 papers
Banu Arun
15 papers
Savitri Krishnamurthy
15 papers
Senthil Damodaran
15 papers
Clinton Yam
13 papers

Grants

Translational Research in Breast Cancer
National Cancer Institute · P50
Project lead · $338K · Baylor College of Medicine
2014–2025

Clinical trials

Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC
Principal investigator · Not yet recruiting · Phase 1
M.D. Anderson Cancer Center
2027–2032
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
Principal investigator · Not yet recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2038
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2025–2029
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2024–2025